Does PALBOCICLIB Cause Neoplasm progression? 10,885 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10,885 reports of Neoplasm progression have been filed in association with PALBOCICLIB (Ibrance). This represents 12.0% of all adverse event reports for PALBOCICLIB.
10,885
Reports of Neoplasm progression with PALBOCICLIB
12.0%
of all PALBOCICLIB reports
1,499
Deaths
1,400
Hospitalizations
How Dangerous Is Neoplasm progression From PALBOCICLIB?
Of the 10,885 reports, 1,499 (13.8%) resulted in death, 1,400 (12.9%) required hospitalization, and 73 (0.7%) were considered life-threatening.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 10,885 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
Decreased appetite (3,400)
What Other Drugs Cause Neoplasm progression?
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
GEMCITABINE (960)
Which PALBOCICLIB Alternatives Have Lower Neoplasm progression Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID